NasdaqGM:RLAYBiotechs
A Look At Relay Therapeutics (RLAY) Valuation After Earnings Update And New Shelf Registration
Annual earnings and new shelf registration reshape Relay Therapeutics story
Relay Therapeutics (RLAY) has just reported its full year 2025 results, pairing higher reported revenue and a smaller net loss with a new US$96.2 million shelf registration for potential common stock issuance.
See our latest analysis for Relay Therapeutics.
The earnings update, new US$96.2 million shelf registration and recent conference appearance come as Relay Therapeutics’ share price trades at US$9.89, with a 90...